SciSparc Ltd. and Clearmind Medicine Inc. have collaborated to publish an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy targeting obesity and high blood sugar. The patent application includes Clearmind's proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA), aiming to treat metabolic syndrome. The collaboration has resulted in 13 patent families across the United States, Europe, and China, focusing on therapies combining neuroplastogens and N-acylethanolamines.

SciSparc Ltd. (NASDAQ:SPRC), a micro-cap pharmaceutical company, announced shareholder vote dates for its proposed merger with AutoMax Motors Ltd. The merger, which involves a reverse acquisition, is set to proceed with shareholder approvals and Israeli court authorization. SciSparc, focused on central nervous system treatments, will acquire 100% of AutoMax, an electric vehicle importer in Israel. The transaction faces closing conditions, including regulatory approvals. Additional news includes SciSparc's patent filings, a share split, and a June 2025 shareholder meeting.

SciSparc Ltd. announced progress in its proposed merger with AutoMax Motors Ltd., a leading electric vehicle importer in Israel. The merger, finalized in April 2024, involves a reverse merger where AutoMax becomes a wholly-owned subsidiary of SciSparc. The SEC declared the registration statement effective on July 21, 2025, and shareholder approvals are pending. SciSparc, a clinical-stage pharmaceutical company, focuses on cannabinoid-based therapies and owns a subsidiary selling hemp seed oil products on Amazon.

SciSparc Ltd. has advanced in its proposed merger with AutoMax Motors, Israel's exclusive importer of JAC electric vehicles. The deal, announced in April 2024, involves SciSparc acquiring 100% of AutoMax's share capital via a reverse merger. Shareholder approvals and Israeli court clearance are required for the transaction, with voting dates set for August 25, 2025 (SciSparc) and August 28, 2025 (AutoMax). The merger aims to shift SciSparc from a clinical-stage pharmaceutical company to an EV importer in Israel, potentially enhancing shareholder value.

IM Cannabis Corp. (IMCC) finalized a $1 million loan agreement with L.I.A. Pure Capital Ltd., with an option to access an additional $1 million. The loan, bearing an 8% annual interest rate, must be repaid by June 30, 2026, and is secured by 100% of IMC Holdings Ltd. shares. Oz Adler, CEO of SciSparc Ltd., was appointed to IMCC's board. The company must raise $3 million within 60 days, with potential early repayment if $5 million is secured. IMCC focuses on sustainable growth in Israel and Germany.